REGN - Emerging and Chinese pharmas playing greater role in oncology drug development
2024-06-02 14:00:00 ET
PD-1/PD-L1 inhibitors, some of the most commonly used cancer therapies, achieved $52B in spending worldwide in 2023, a number expected to reach $90B in 2028. Examples include Merck's ( NYSE: MRK ) Keytruda (pembrolizumab), Bristol Myers Squibb's ( NYSE: BMY ) Opdivo (nivolumab), Regeneron Pharmaceuticals' ( REGN ) Libtayo (cemiplimab), Merck KGaA's ( OTCPK:MKGAF )( OTCPK:MKKGY ) Bavencio (avelumab), Roche's ( OTCQX:RHHBY ) Tecentriq (atezolizumab), and AstraZeneca's ( NASDAQ: AZN ) Imfinzi (durvalumab)....
Emerging and Chinese pharmas playing greater role in oncology drug development